Skip to main content
Top

18-06-2018 | Osteoporosis | Article

Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study

Journal: Pediatric Rheumatology

Authors: Yuzaburo Inoue, Kanako Mitsunaga, Takeshi Yamamoto, Koki Chiba, Fumiya Yamaide, Taiji Nakano, Yoshinori Morita, Akiko Yamaide, Shuichi Suzuki, Takayasu Arima, Ken-ichi Yamaguchi, Minako Tomiita, Naoki Shimojo, Yoichi Kohno

Publisher: BioMed Central

Abstract

Background

Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children remains unclear.

Methods

We performed a cross-sectional study to clarify the factors associated with the development of glucocorticoid-induced bone loss and osteoporosis in patients with childhood-onset rheumatic disease and to investigate the impact of the early use of alendronate. We recruited 39 patients with childhood-onset rheumatic disease who were evaluated to detect bone loss or osteoporosis at 3 months to 1.5 years after the initiation of treatment. The primary outcome of the study was the presence of bone loss or osteoporosis at the initial evaluation of the bone mineral density after at least 3 months of glucocorticoid therapy.

Results

Bone loss and a history of fracture were found in 56 and 18% of the participants, respectively. Weekly oral alendronate therapy (median, 25.4 mg/m2) had been started by the time of the evaluation of osteoporosis in 46% of the participants and within 3 months after the start of glucocorticoid in 31% of the participants. There were no significant differences between the participants with bone loss (wBL group) and without bone loss (w/oBL group) in terms of gender, primary disease, or the age at the onset of primary disease. In terms of glucocorticoid use, there was no significant difference in the age at the start of glucocorticoid therapy, the length of glucocorticoid use, or the dose of glucocorticoids. The proportion of patients in the w/oBL group who received alendronate within 3 months after the start of glucocorticoid therapy was significantly greater than that in the wBL group. In the logistic regression analysis, only “alendronate therapy within 3 months after the start of glucocorticoid therapy” had a statistically significant effect on the development of bone loss (OR, 0.08; 95% CI, 0.02–0.43). The analysis did not reveal any factors associated with the development of osteoporosis.

Conclusions

The early use of alendronate may have a preventive effect against the development of bone loss in glucocorticoid-treated patients with childhood-onset rheumatic disease.
Literature
1.
Von Scheven E, Corbin KJ, Stefano S, Cimaz R. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014;12:289–99.CrossRefPubMed
2.
van Staa TP, Cooper C, Leufkens HGM, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res [Internet]. 2003;18:913–918. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12733732
3.
Bonjour J-P, Chevalley T, Ferrari S, Rizzoli R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex [Internet]. 2009 [cited 2017 Dec 18];51 Suppl 1:S5–17. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19287894
4.
Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van’t Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med [Internet]. 1993 [cited 2017 Dec 18];119:963–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8105737
5.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken) [Internet]. 2017;69:1095–110. Available from: http://​doi.​wiley.​com/​10.​1002/​acr.​23279
6.
Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest [Internet]. 1996 [cited 2017 Dec 17];97:2692–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8675678
7.
Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M, et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol [Internet]. 2008 [cited 2012 Mar 14];27:909–12. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18330609
8.
Nishiyama S, Okada T. Bone mineral density in Japanese children and adolescents. Clin Pediatr Endocrinol [Internet]. 2001 [cited 2017 Oct 27];10:113–20. Available from: https://​www.​jstage.​jst.​go.​jp/​article/​cpe/​10/​2/​10_​2_​113/​_​pdf
9.
Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: The ISCD 2013 pediatric official positions. J Clin Densitom [Internet]. Elsevier Ltd; 2014;17:275–80. Available from: https://​doi.​org/​10.​1016/​j.​jocd.​2014.​01.​004
10.
Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res [Internet]. 2009 [cited 2017 Nov 5];8:1137–48. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8237484
11.
Haugeberg G, Griffiths B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis [Internet]. 2004;63:940–4. Available from: http://​www.​pubmedcentral.​nih.​gov/​articlerender.​fcgi?​artid=​1755089&​tool=​pmcentrez&​rendertype=​abstract.
12.
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. United States. 1995;58:288–98.CrossRefPubMed
13.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet [Internet]. Elsevier Ltd; 2009;373:1253–63. Available from: https://​doi.​org/​10.​1016/​S0140-6736(09)60250-6
14.
Nakagi Y, Ito T, Hirooka K, Sugioka Y, Endo H, Saijo Y, et al. Association between lifestyle habits and bone mineral density in Japanese juveniles. Environ Health Prev Med. 2010;15:222–8.CrossRefPubMedPubMedCentral
15.
Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) [Internet]. 2012 [cited 2014 May 9];64:122–31. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22213727.